ContraVir Pharmaceuticals (NASDAQ:CTRV) completed dosing of the last cohort of healthy subjects for its CRV431 drug-drug interaction (DDI) study. The single-dose crossover study evaluated subjects co-treated with...
Knight Therapeutics (TSX:GUD) announced the Canadian launch of Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine subdermal implant of buprenorphine hydrochloride for the management of opioid dependence in patients...
An Oct. 26 article on the Washington Post web site discusses job openings in Canada’s legalized cannabis sector, highlighting an Ontario government policy advisor who left his job to join Lobo Genetics as its director...
Closely-held Mati Therapeutics’ international patent portfolio has grown to 114 issued patents, including a recently granted U.S. patent, which covers a drug delivery system for administering an ophthalmic drug through...
Closely-held Scientus Pharma received Health Canada authorization to produce cannabis soft gel capsules and oils at its state-of-the-art commercial production facility in Whitby, Ontario. “At Scientus Pharma, our main...
In the latest edition of Scientific American online, Dr. Gina Siddiqui, an emergency room doctor at Yale New Haven Hospital, discusses why physicians have incorrectly feared that new technology would make their jobs...
Ortho Regenerative Technologies (CSE:ORTH) presented a poster entitled, “Freeze-dried [Ortho-R] in Platelet-rich Plasma in Sheep Model of Rotator Cuff Repair,” at the SICOT Orthopaedic World Congress in Montreal. The...
CHF Solutions (NASDAQ:CHFS) and NI Medical are collaborating to explore potential clinical synergies between CHF’s Aquadex FlexFlow System and NI Medical’s NICaS Hemodynamic Navigator to assess patient’s fluid volume...
BioLight Life Sciences (OTCQX:BLGTY; TASE:BOLT) has completed the second stage of the investment in and acquisition in stages of its subsidiary, IOPtima, by Chengdu Kanghong Pharmaceutical Group of China. Under the...
Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) has completed enrollment for the Phase 3 AURORA trial ahead of schedule. The target enrollment of 324 patients was surpassed due to high patient demand with 358 lupus...
Three-year clinical outcomes and a subgroup analysis of benign prostatic hyperplasia (BPH) patients enrolled in Profound Medical’s (TSX:PRN; OTCQX:PRFMF) earlier Phase 1 safety and feasibility study of TULSA-PRO will be...
Closely-held CellAegis Devices completed enrollment in an investigator sponsored study (FIRST) to evaluate the clinical and economic benefits of remote ischemic conditioning (RIC) therapy in the treatment of patients...
Titan Pharmaceuticals (NASDAQ:TTNP) was awarded a two-year grant of about $6.7-million from the NIH’s National Institute on Drug Abuse (NIDA) for the development of a ProNeura-based six-month implantable formulation of...
Closely-held Mati Therapeutics reported encouraging results from a planned interim analysis of an ongoing Phase 2 clinical trial evaluating the safety and efficacy of nepafenac delivered in Mati’s Evolute sustained...
Ortho Regenerative Technologies (CSE:ORTH) entered into an agreement with a leading contract manufacturing organization operating within the global biopharmaceutical industry to begin work on providing Ortho RTi with...
Titan Pharmaceuticals (NASDAQ:TTNP) launched a pilot program in collaboration with the Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Titan’s Probuphine (buprenorphine)...
Closely-held Urovant Sciences licensed from Ion Channel Innovations global rights for an investigational gene therapy, hMaxi-K, for patients with overactive bladder (OAB) symptoms, who have failed oral pharmacologic...
Esperion (NASDAQ:ESPR) reported positive top-line results from a Phase 3 study of its bempedoic acid/ezetimibe combination pill for the treatment of LDL-C lowering. The study included 382 high-risk patients taking...
Sierra Oncology (NASDAQ:SRRA) has acquired the drug candidate, momelotinib, from Gilead Sciences (NASDAQ:GILD) for a $3-million upfront fee and potential milestone payments of up to $195-million, which are largely...
The FDA has accepted for review Evoke Pharma’s (NASDAQ:EVOK) 505(b)(2) NDA for Gimoti, the company’s nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic...
electroCore (NASDAQ:ECOR) is collaborating with Massachusetts General Hospital (MGH) in a neuroinflammation research program. Under the program, electroCore’s non-invasive vagus nerve stimulation (nVNS) will be studied...
A new study published in the peer-reviewed journal, Dysphagia, suggests that the proportion of seniors with swallowing problems in the U.S. is expected to top 20% by 2030 from 15% currently. “Dysphagia has...